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Clusterin accumulates in synapses in
Alzheimer’s disease and is increased in
apolipoprotein E4 carriers
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Tara L. Spires-Jones1
One of the major challenges in developing effective therapeutic strategies for Alzheimer’s disease is understanding how genetic risk
factors contribute to neurodegeneration. The apolipoprotein epsilon 4 isoform (APOE4) and variants in the Clusterin (CLU) gene
(also known as apolipoprotein J) are associated with increased risk of developing Alzheimer’s. Our previous work demonstrated
that APOE4 exacerbates synapse degeneration and synaptic accumulation of toxic oligomeric amyloid beta in human Alzheimer’s
and mouse models of disease. Here, we observe clusterin in synapses in human Alzheimer’s disease brain. The percentage of synap-
ses containing clusterin is higher in APOE4 carriers than APOE3 carriers. Furthermore, we observe oligomeric amyloid beta accu-
mulation within synapses containing clusterin which is also higher in APOE4 carriers. These data link two genetic risk factors with
synapse degeneration in Alzheimer’s and support a potential role for clusterin working with APOE in causing synaptic damage.
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Introduction
Alzheimer’s disease, a devastating neurodegenerative dis-
ease, is characterized neuropathologically by the presence
of amyloid beta (Ab) plaques and tangles made of hyper-
phosphorylated and misfolded tau, as well gross neuron
and synapse loss in affected areas. Of these hallmarks, it
is synapse loss that correlates most strongly with the cog-
nitive decline experienced by people living with
Alzheimer’s disease (Spires-Jones and Hyman, 2014).
Data from animal models of Alzheimer’s disease demon-
strate that dysfunction of synapses and disrupted synaptic
plasticity are key components of neurodegeneration in
Alzheimer’s disease (Crimins et al., 2013). Investigating
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the protein changes that underlie the synaptic degener-
ation caused by Alzheimer’s disease is crucial to our
understanding of the pathological pathways that are initi-
ated by this disease.
Although most cases of Alzheimer’s disease are not dir-
ectly heritable, genetic risk factors have been identified,
the strongest of which is the epsilon 4 isoform of apoli-
poprotein E (APOE4). The APOE4 allele has been
shown to increase the risk of Alzheimer’s disease in a
dose-dependent manner when compared with the more
common APOE3 allele whereas the rarer APOE2 allele
is protective (Corder et al., 1993; Corder and Roses,
1996). The possession of two copies of APOE4 has been
shown to not only increase the chance of getting
Alzheimer’s disease by 12-fold that of a person with two
copies of APOE3, but also lower the average age of clin-
ical onset to 68 years of age down from 84 (Corder
et al., 1993). APOE4 has also been shown to affect the
speed of cognitive decline in both Alzheimer’s disease
individuals as well as having an effect on the cognitive
function of non-demented older adults (Schiepers et al.,
2012; Lim et al., 2015).
Our previous work has shown that in both a mouse
model of Alzheimer’s disease and human post-mortem tis-
sue from Alzheimer’s disease individuals synapse density
is decreased inside the Ab plaque core and the Ab oligo-
mer containing halo. This loss of synapse density returns
to near control levels when greater than 35 lm from the
Graphical Abstract
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plaque halo (Koffie et al., 2009, 2012). Furthermore, we
saw a significantly lower density of synapses near plaques
in APOE4 carriers compared with APOE3 carriers and
the density of synapses far from plaques was also signifi-
cantly lower (Koffie et al., 2012). We have recently com-
pleted a systematic literature search and comprehensive
review of the published papers relating ApoE to neurode-
generation, inflammation and/or the spread of pathologic-
al proteins through the brain (Tzioras et al., 2019). The
review of the 108 papers that matched our inclusion cri-
teria shows strong evidence in the field implicating
APOE4 in synapse degeneration, neurodegeneration and
inflammation and highlighted the need for a better under-
standing of the mechanisms through which APOE affects
synapse degeneration. One potential mechanism leading
from APOE4 to synapse loss is via interacting with other
genetic risk factors to influence accumulation of toxic
oligomers of Ab in synapses.
Genome wide association studies over the past decade
uncovered additional risk factors to APOE4 including
TREM2, PICALM and CLU (Harold et al., 2009;
Guerreiro et al., 2013). Clusterin, also called apolipopro-
tein J, is the second most abundant apolipoprotein in the
human brain and has crucial roles in trafficking and
clearance of Ab similar to the role played by ApoE
(Nuutinen et al., 2009). Indeed, there are many parallels
between clusterin and ApoE that make an interaction be-
tween them of interest, not least of which is that both
have been shown to act as a modulator of multiple path-
ways of interest during diseases and aging including; glu-
cose metabolism, transport of cholesterol, amyloid beta
trafficking and regulation of the immune system (Hakkoum
et al., 2008; Park et al., 2014; Foster et al., 2019).
In this study, we tested the hypothesis that clusterin
and ApoE4 work together to cause synapse degeneration
in Alzheimer’s disease by increasing accumulation of oli-
gomeric amyloid beta at synapses. To achieve this, we
isolated synaptoneurosomes from post-mortem tissue of
Alzheimer’s disease and non-demented control individuals
of known APOE genotypes which were then probed for
clusterin levels. We also used the high-resolution imaging
technique array tomography to further assess the impact
of ApoE4 and Alzheimer’s disease on the synaptic local-
ization of Ab and clusterin and the related impact on the
loss of synaptic density in Alzheimer’s disease. We ob-
serve accumulation of clusterin in synapses which is
higher in APOE4 carriers than APOE3 carriers.
Materials and methods
All materials were purchased from Sigma-Aldrich unless
otherwise stated.
Human subjects
Tissue from superior temporal cortex, Brodmann Area
41/42 of human subjects with Alzheimer’s disease or no
neurological phenotype was used for this study. Table 1
shows characteristics of the human subjects.
Use of human tissue for post-mortem studies was
reviewed and approved by the Edinburgh Brain Bank eth-
ics committee and the medical research ethics committee
(the Academic and Clinical Central Office for Research
and Development, a joint office of the University of
Edinburgh and NHS Lothian, approval number 15-HV-
016). The Edinburgh Brain Bank is a Medical Research
Council funded facility with research ethics committee
(REC) approval (11/ES/0022).
APOE genotyping
DNA was extracted from 25mg of cerebellum tissue
sampled from each case using the QIAamp DNA mini kit
(Qiagen, Hilden, Germany) according to manufacturer’s
instructions. Polymerase chain reaction (PCR) was per-
formed on the extracted DNA. PCR using Master mix
(Promega, Madison, WI) and contained 1lM of primer
and 10% DMSO. The forward primer was 50-taagcttgg-
cacggctgtccaagg-30 and the reverse primer 50-aca-
gaattcgccccggcctggtacactgcc-30. Pure APOE 2, APOE 3
and APOE 4 DNA were amplified by PCR to use as
positive controls. The reactions were then heated to 94C
for 10 min before being cycled 32 times in a thermal
cycler (Thermo Fisher Scientific, Waltham, MA). The
cycle consisted of 30 s of denaturing at 94C, 30 s of
annealing at 56C and then 1 min of elongation at 72C.
The product from PCR was then digested with the re-
striction enzyme HhaI (New England Biolabs, Ipswich,
MA) overnight at 37C. Digested DNA was then loaded
onto Novex TBE 20% pre-cast gels with 15 wells
(Thermo Fisher Scientific, Waltham, MA) and separated
by size using electrophoresis for 2 h at 200V. Gels were
then removed from the cassette incubated with SYBR
safe DNA Gel Stain (Thermo Fisher Scientific, Waltham,
MA) and visualized using UV light on a gene genius bio
imaging system (Syngene, Cambridge, UK). The banding
pattern indicated APOE genotype.
Synaptoneurosome isolations and
western blotting
Synaptoneurosomes and crude homogenate preparations
were biochemically isolated according to Tai et al.
(2012). Approximately 200 mg of fresh-frozen brain tis-
sue from human Alzheimer’s disease and control tem-
poral cortex was homogenized in a glass homogenizer
with 1 ml ice-cold buffer A (5mmol/L KCl, 1mmol/L
MgCl2, 25mmol/L HEPES pH 7.5, 120mmol/L NaCl
and 2mmol/L CaCl2), supplemented with 2mmol/L DTT,
protease inhibitors (cOmplete mini, Roche, Basel,
Switzerland), and phosphatase inhibitors (Millipore,
Billerica, MA). Homogenates were filtered through two
layers of 80-lm nylon filters (Millipore, Billerica, MA). A
solution of 200 ll of this filtered homogenate was mixed
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Table 1 Human subject characteristics
Case ID Diagnosis APOE genotype age (range) sex (m,f) Braak stage PMI (hours6
stdev)
cases used for western blot
20122 non-demented control 3/3 59 M 0 74
14395 non-demented control 3/3 74 F 0 41
19686 non-demented control 3/3 77 F I 75
22612 non-demented control 3/3 61 M 0 70
001.26475 non-demented control 3/3 78 M I 39
24340 non-demented control 3/3 53 M 0 53
001.28406 non-demented control 3/3 79 M II 72
001.28793 non-demented control 3/3 79 F II 72
001.28402 non-demented control 3/3 79 M I 49
GROUP n59 59 (53-79) 6,3 I 746 15
15221 non-demented control 4/3 53 M 0 114
15809 non-demented control 4/3 58 M 0 90
20593 non-demented control 4/3 60 M 0 52
16425 non-demented control 4/3 61 M 0 99
001.2555 non-demented control 4/3 74 M 0 66
22629 non-demented control 4/3 59 F 0 53
GROUP n56 61 (53-74) 5,1 0 796 26
19994 Alzheimer’s disease 3/3 87 F VI 89
15258 Alzheimer’s disease 3/3 65 M VI 80
001.19595 Alzheimer’s disease 3/3 87 M VI 58
001.28410 Alzheimer’s disease 3/3 62 F VI 109
22223 Alzheimer’s disease 3/3 87 F IV 83
24527 Alzheimer’s disease 3/3 81 M V 74
001.28771 Alzheimer’s disease 3/3 85 M VI 91
001.28785 Alzheimer’s disease 3/3 78 F No stageing 76
GROUP n58 79 (62-87) 4,4 VI 836 15
10591 Alzheimer’s disease 4/3 86 M VI 76
15810 Alzheimer’s disease 4/3 73 F VI 96
001.15811 Alzheimer’s disease 4/3 81 F VI 41
15259 Alzheimer’s disease 4/3 87 F VI 28
23394 Alzheimer’s disease 4/3 88 F V 59
001.24322 Alzheimer’s disease 3/4 80 M VI 101
24526 Alzheimer’s disease 3/4 79 M VI 65
19690 Alzheimer’s disease 3/4 57 M VI 58
001.25739 Alzheimer’s disease 3/4 85 F VI 45
001.26718 Alzheimer’s disease 3/4 78 M VI 74
001.26732 Alzheimer’s disease 3/4 76 M VI 66
GROUP n511 79 (57-88) 6,5 VI 646 22
cases used for array tomography
001.28406 non-demented control 3/3 79 M II 72
001.26495 non-demented control 3/3 78 M I 39
001.28793 non-demented control 3/3 79 F II 72
19686 non-demented control 3/3 77 F I 75
001.28797 non-demented control 3/3 79 M 0 57
GROUP n55 78 (77-79) 3,2 I 636 15
1424 Alzheimer’s disease 3/3 89 M VI 25
001.28410 Alzheimer’s disease 3/3 62 F VI 109
001.28771 Alzheimer’s disease 3/3 85 M VI 91
24527 Alzheimer’s disease 3/3 81 M V 74
GROUP n54 79 (62-89) 3,1 VI 746 36
001.25739 Alzheimer’s disease 4/3 85 F VI 45
001.26718 Alzheimer’s disease 4/3 78 M VI 74
24526 Alzheimer’s disease 4/3 79 M VI 65
19690 Alzheimer’s disease 4/3 57 M VI 58
001.26732 Alzheimer’s disease 4/3 76 M VI 66
001.29521 Alzheimer’s disease 4/3 95 M VI 96
001.29135 Alzheimer’s disease 4/3 90 M VI 73
GROUP n57 80 (57-95) 6,1 VI 686 16
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with 200 ll water and 70 ll 10% sodium dodecyl sul-
phate (SDS) and boiled to prepare the crude homogenate
fraction.
To prepare synaptoneurosomes, the remainder of the
filtered homogenate was passed through a 5-lm mem-
brane filter (Durapore, Millipore, Billerica, MA) before
being centrifuged at 1000G for 10 min. The supernatant
was removed, and the pellet resuspended in 200 ll buffer
A and centrifuged again at 1000 G for 5 min. The super-
natant was discarded and the synaptoneurosome pellets
were snap frozen on dry ice and then transferred to
80C.
Synaptoneurosome pellets were resuspended in 400 ll
of Buffer B (50mmol/L Tris [pH 7.5], 1.5% SDS and
2mmol/L DTT) and boiled for 5 min. 10% SDS was
added to the supernatant fraction to bring it up to 1.5%
SDS and this was also boiled for 5 min to prepare for
western blotting. Protein concentration in each sample
was estimated by bicinchoninic acid (BCA) assay.
Synaptoneurosomes or crude homogenate preparations
were loaded onto 15 well NuPAGE 4–12% Bis-Tris pre-
cast polyacrylamide gels (Invitrogen, Paisley, UK) along
with molecular weight marker (Li-Cor, Cambridge, UK).
Proteins were transferred to nitrocellulose membranes
(Bio-Rad, Hemel Hempstead, UK), which were probed
with the following primary antibodies: b-actin (ab8226,
Abcam, 1:2000), Synaptophysin (ab8049, Abcam,
1:10 000), GAPDH (ab8245, Abcam, 1:2000), Histone
H3 (1:1000, ab1791, Abcam), PSD95 (1:1000, D27E11,
Cell Signaling Technology) and clusterin (1:500, sc-8354,
Santa Cruz Biotechnology). After rinsing off unbound pri-
mary antibodies, membranes were incubated with 680
and 800 IR dye labelled secondary antibodies (1:50 000,
LI-COR Biosciences) and visualized on an odyssey infra-
red system (LI-COR Biosciences).
Array tomography
Tissue from the BA41/42 area of the cortex was
embedded as described in Kay et al. (2013). In brief,
post-mortem samples were collected at autopsy, cut into
small cortical blocks and fixed in 4% paraformaldehyde
for 2–3 h. Samples were then dehydrated in ascending
concentrations of ethanols and incubated in LR white
resin overnight. Cortical blocks were then baked in LR
white resin which was polymerized at 56C for 24 h.
Tissue blocks were sectioned into ribbons of 70 nm serial
sections which were collected on gelatin-coated coverslips.
The ribbons were stained with primary and secondary
antibodies and the same region of interest imaged in each
section of the ribbon. Antibodies from the first day of
staining were eluted off of the ribbon in stripping buffer
(0.2 m NaOH, 0.02% SDS in dH2O) then ribbons were
re-probed with a second set of antibodies and images
were taken in the same regions of interest as day 1. The
primary antibodies on day 1 was 1C22 [1:50, kind gift
of Dominic Walsh (Yang et al., 2015)]. Primary
antibodies used on day 2 were mouse anti-synaptophysin
(1:50, ab8049, Abcam), and goat anti-clusterin (1:50, sc-
6420, Santa Cruz Biotechnologies). The Alexa Fluor con-
jugated secondary antibody used on day 1 was donkey
anti-mouse 594 (Invitrogen). Secondary antibodies used
on day 2 were donkey anti-mouse 594 (A31571) and
donkey anti-goat 594 (A11058, Invitrogen). All secondary
antibodies were used at a 1:50 dilution and DAPI was
used on both days to label nuclei. Images were acquired
with a Zeiss Axio Imager Z2 upright microscope
equipped with a CoolSnap digital camera using a 63 oil
objective. Images were acquired from the same location
on each serial section of the ribbon. Image stacks were
aligned and regions of interest in the neuropil selected in
image J using custom macros and the multistack reg plu-
gin (Thevenaz et al., 1998; Micheva et al., 2010).
Custom MATLAB scripts were used to detect synaptic
puncta and determine whether clusterin and/or Ab stain-
ing was present in each synapse.
Statistical analysis
The experimental unit for all experiments was a mean or
median for each subject. The experimenter was blind to
condition during image analysis. Numbers of subjects in
each group can be found in Table 1. Statistics were cal-
culated using graph pad prism (version 7.0c). Normality
was tested with the Shapiro–Wilk normality test. For
parametric data (western blots and synapse density) one
or two-way ANOVA was used to compare groups fol-
lowed by Tukey’s post hoc tests between individual pairs
of groups. Co-localization data of the percentage of syn-
apses containing Ab, clusterin or both were not normally
distributed thus were analysed with Kruskal–Wallis tests
followed by post hoc Mann–Whitney U test between per-
tinent groups.
Data availability
Data from Western blot experiments for each case can be
found in Supplementary Table 1, and data from array
tomography experiments can be found in Supplementary
Table 2. Raw images are available from the correspond-
ing author upon request. Custom image analysis macros
for array tomography can be downloaded from https://
doi.org/10.7488/ds/2268
Results
Clusterin is increased in the
Alzheimer’s disease APOE4 synapse
but not in crude homogenate
To investigate the effects of ApoE4 on the amount of clus-
terin in the synapse, synaptoneurosomes were prepared
using a previously described method (Tai et al., 2012).
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The synaptically enriched fraction was probed for synapto-
physin (for pre-synapses) and PSD95 (for post-synapses) to
ensure enrichment of synaptic elements as well as histone
H3 to ensure exclusion of a nuclear marker (Fig. 1).
Samples which contained histone or did not show enrich-
ment of the synapse were either remade or discarded from
the study.
To determine the quality of protein in our human brain
samples, we assessed protein degradation using the
‘HUSPIR’ ratio or (Baye´s et al., 2014). To find this
value, synaptoneurosmes were run on western blot and
probed with an antibody against NMDAR2B antibody.
This recognizes two to three bands, the full length
protein at 170 kDa and degradation products at 150
kDa and below. This degradation product is only found
post-mortem and not in autopsy tissue thus comparing
these two bands is a good indication of post-mortem
protein integrity. Samples with a degradation ratio of
less than 1 were excluded from the study (data not
shown).
Western blot analysis of homogenate of temporal cor-
tex from post-mortem brain (Fig. 2A, un-cropped western
blots are shown in Supplementary Figs 1 and 2) shows
an increase in the amount of clusterin in Alzheimer’s dis-
ease compared with control, with no effect of APOE
genotype on this increase (two-way ANOVA effect of dis-
ease F (1, 30)¼ 16.96, P¼ 0.0003, effect of APOE geno-
type F (1, 30) < 0.0001, P¼ 0.998; Tukey’s post hoc
between control APOE3 and Alzheimer’s disease APOE3
P¼ 0.0241, Tukey’s post hoc between Control APOE4
and Alzheimer’s disease APOE4 P¼ 0.0421, Fig. 2C).
This is consistent with previous studies, although a recent
study indicated that clusterin is increased in Alzheimer’s
disease due in part to its interaction with Ab plaques
(Miners et al., 2017). As Ab plaques are more prevalent
in individuals with an APOE4 genotype one might expect
Figure 1 Preparation of synaptoneurosomes. Crude homogenates (H) and synaptoneurosomes pellets (P) were isolated from
temporal cortex of Alzheimer’s disease and control subjects. Representative western blots (A) and quantification of synaptic proteins
(B) is shown for seven cases (indicated by their BBN ID numbers 14395, 15221, 15809, 16425, 19686, 20122 and 20593). Enrichment of synaptic
proteins (synaptophysin and PSD95) and exclusion of nuclear histone protein in the synaptoneurosome pellets compared with the homogenates
was confirmed for each case included in the study. GAPDH is used to ensure equal protein loading.
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a slight increase in the amount of clusterin in
Alzheimer’s disease APOE4 cases compared with
Alzheimer’s disease APOE3 cases (Rebeck et al., 1993).
However, this is not seen in our cases, potentially be-
cause any effect of APOE4 on clusterin is diluted by
the rest of the cellular milieu. In contrast, western blot
analysis of synaptoneurosomes shows an increase in
clusterin in Alzheimer’s disease cases (Fig. 2B, two-way
ANOVA effect of disease F (1, 30)¼ 44.24, P< 0.0001,
effect of APOE genotype F (1, 30)¼ 2.48, P¼ 0.126,
interaction F (1, 30)¼ 4.551, P¼ 0.0412, Tukey’s post
hoc between control APOE3 versus Alzheimer’s disease
APOE3 P¼ 0.0137 and Tukey’s post hoc between con-
trol APOE4 versus Alzheimer’s disease APOE4
P< 0.0001) and a further increase in the Alzheimer’s
disease APOE4 cases compared with Alzheimer’s disease
APOE3 (Tukey’s post hoc P¼ 0.0413, un-cropped blots
are shown in Supplementary Fig. 2). This indicates that
an APOE4 genotype increases the amount of clusterin
at remaining synapses in Alzheimer’s disease but not
overall in the temporal cortex. Further analysis shows
that within the Alzheimer’s disease APOE4 cases,
more than in any other group, the amount of clusterin
found at the synapse is higher than the amount found
in the crude homogenate from the same case, indicating
that clusterin is increased specifically in the synapse in
these cases (Supplementary Fig. 3). Analysis of western
blot data for each case can be found in Supplementary
Table 1.
APOE4 is associated with
exacerbated synaptic loss and
increased synaptic A
co-localization in Alzheimer’s
disease
While western blots allow measurements of protein abun-
dance in synaptoneurosomes, they do not provide
detailed information about synapse loss, specific changes
Figure 2 Clusterin is increased in the synaptic compartment in Alzheimer’s disease with highest levels in APOE4 carriers.
Western blot (A, B) analysis shows an increased level of clusterin when comparing Control with Alzheimer’s disease in both Crude Homogeante
(A, C) and in Synaptically enriched preps (B, D). In synapses, there is a further increase in the Alzheimer’s disease APOE4 cases compared with
Alzheimer’s disease APOE3 cases (*Tukey’s post hoc tests, P< 0.05).
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in synapses near plaques or the co-localization of multiple
proteins within synapses. Thus to test the hypothesis that
APOE genotype affects the synaptic accumulation of clus-
terin and Ab, we used the high-resolution array tomog-
raphy technique (Micheva et al., 2010), which we have
optimized for use in human post-mortem tissue (Koffie
et al., 2012; Kay et al., 2013). Using this technique, we
can observe the co-localization of clusterin and Ab within
individual pre-synaptic terminals as well as examining
synapse density (Fig. 3). Due to limited sample availabil-
ity of tissue prepared at autopsy for this specialized tech-
nique, we did not have enough subjects for a control
APOE4 group. In a previous study using array tomog-
raphy, we observed that APOE4 exacerbates synapse loss
near plaques and is associated with increases in the per-
centage of synapses containing Ab (Koffie et al., 2012).
Here, we replicate these findings in a different set of sub-
jects (Fig. 4A and B), and further examine clusterin and
Ab in synapses. Regions of interest in the neuropil were
selected from image stacks and divided into two groups,
those which were near plaques (<10 lm from plaque
edge) and those far from plaques (>45 lm from plaque
edge). Synaptophysin was used as a marker of pre-synap-
tic terminals. Consistent with our previous study (Koffie
et al., 2012), we observe a loss of synapses in Alzheimer’s
disease compared with control brain, the loss being exacer-
bated near plaques in APOE4 cases (one-way ANOVA,
F(4.22)¼ 14.2, P< 0.0001, post hoc Tukey’s tests
Alzheimer’s disease APOE4 near versus far from plaques
P¼ 0.032, control versus Alzheimer’s disease APOE4 near
P< 0.0001). Further, there is a significant drop in pre-syn-
aptic density near plaques when compared with far from
plaques in Alzheimer’s disease cases (two-way ANOVA ef-
fect of plaque distance, F (1, 18)¼ 11.21, P¼ 0.0036) and
a significant effect of APOE genotype on synapse density
(two-way ANOVA effect of APOE genotype, F (1,
18)¼ 16.67, P¼ 0.0007, Fig. 4A). Also consistent with
previous data was the finding that synapses near plaques
Figure 3 Representative images of array tomography staining. Array tomography ribbons from non-demented controls (NDC),
Alzheimer’s disease APOE3 and Alzheimer’s disease APOE4 individuals were stained for pre-synapses (synaptophysin, yellow), oAb (1C22, cyan)
and clusterin (magenta). Images shown in (A) are maximum intensity projections of four serial sections (aligned raw images). Images shown in
(B) are maximum intensity projections of two serial sections from analysed image stacks that have been thresholded and single section noise
removed in MATLAB. Each channel is shown separately with the merge in the bottom image. Arrows indicate synapses containing both clusterin
and oAb staining. Scale bars represent 15 lm (A) and 1 lm (B).
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were significantly more likely to co-localize with Ab
(Fig. 4B, Kruskal–Wallis test v2(4)¼ 21.18, P¼ 0.0003,
post hoc Mann–Whitney U between Alzheimer’s disease
APOE3 near and APOE3 far P¼ 0.0286 and between
Alzheimer’s disease APOE4 near and APOE4 far
P¼ 0.0006) and that this increase was greater in APOE4
Alzheimer’s disease cases (post hoc Mann–Whitney U be-
tween Alzheimer’s disease APOE3 near versus Alzheimer’s
disease APOE4 near P¼ 0.0061). Analysis of array tom-
ography data for each case can be found in
Supplementary Table 2.
APOE4 is associated with an
increased synaptic co-localization of
clusterin and increased synaptic
co-localization of clusterin and
oligomeric A
Array tomography was used to investigate whether the
increase in clusterin seen in the synaptoneurosome using
proteomics and western blot was associated with accumu-
lation of clusterin and Ab within the same synapses.
Figure 4 Analysis of synaptic punctate by array tomography. (A)There is a significant decrease in the pre-synaptic density in
Alzheimer’s cases near plaques (<10 lm) compared with far from plaques (>45 lm) which is exacerbated by APOE4 genotype (one-way
ANOVA F [4, 22] ¼ 14.2, P< 0.0001). (B) There is also a significant increase in the percent of Ab (1C22) positive synapses near plaques
compared with far from plaques that is most pronounced in E4 cases (Kruskal–Wallis test, P¼ 0.0003). (C) Clusterin in pre-synaptic terminals
is increased in Alzheimer’s disease APOE4 carriers (Kruskal–Wallis, P¼ 0.0003). (D) Similarly, the percentage of synapses containing both
clusterin and Ab is highest in Alzheimer’s disease APOE4 carriers near plaques carriers (Kruskal–Wallis, P¼ 0.0002). (*P< 0.05, **P< 0.01,
****P< 0.0001 Tukey’s post hoc test. #P< 0.05, ##P< 0.01, ###P< 0.001 post hoc Mann–Whitney U.) Each symbol represents the mean for a single
case in (A) with error bars representing standard deviation. Each symbol in (B–F) represents the median for a single case with the error bars
showing inter-quartile ranges.
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When the percentage of synapses co-localizing with
clusterin was examined, we observed an increase in
Alzheimer’s disease cases compared with controls with
the largest effect near plaques in APOE4 carriers
(Fig. 4C, Kruskal–Wallis test v2(4)¼ 21.16, P¼ 0.0003;
post hoc Mann–Whitney U between Alzheimer’s disease
APOE3 near and APOE3 far P¼ 0.0286, between
Alzheimer’s disease APOE4 near and APOE4 far
P¼ 0.0023, between Alzheimer’s disease APOE3 far and
Alzheimer’s disease APOE4 far P¼ 0.012, and between
control and APOE4 far P¼ 0.0025).
One of the benefits of array tomography is the ability to
strip antibodies and re-probe the same tissue ribbon with
different antibodies thus allowing the analysis of the co-lo-
calization of several protein markers to the same synapse.
We therefore looked at the co-localization of clusterin and
Ab together at the synapse to see if Alzheimer’s disease
APOE4 cases were more likely to have synapses positive
for both markers. There is an increase in the percentage of
synaptic puncta co-localizing with both Ab and clusterin in
Alzheimer’s disease APOE4 cases near plaques (Fig. 4D,
Kruskal–Wallis test v2(4)¼21.61, P¼ 0.0002, post hoc
Mann–Whitney U between Alzheimer’s disease APOE3
near and APOE3 far P¼ 0.0286, between Alzheimer’s dis-
ease APOE4 near and APOE4 far P¼ 0.0006 and be-
tween Alzheimer’s disease APOE3 near and Alzheimer’s
disease APOE4 near P¼ 0.0061).
Discussion
The effects of ApoE in Alzheimer’s disease have long
been studied but by comparison the study of the related
apolipoprotein clusterin has been limited despite it too
being a genetic risk factor for the disease. Here, we show
by multiple systems in post-mortem tissue that an
APOE4 genotype affects the concentration of clusterin
specifically in the synapse and but not in the brain hom-
ogenate overall. Moreover, this increase in clusterin is
found to coincide with an increase in the amount of Ab
in the same synapses.
As the second most abundantly expressed apolipopro-
tein in the brain, clusterin performs many of the same
roles as ApoE including the transport of cholesterol and
other necessary lipids to the neuron (Dong et al., 2017),
thus it is possible that changes in clusterin and ApoE
may be related. An APOE4 genotype has been shown to
have an effect on the amount of ApoE in the brain due
in part to the increased speed with which ApoE4 is
degraded (Riddell et al., 2008). When Apoe is knocked
out of a mouse line there is an increase in the amount of
clusterin mRNA indicating that clusterin can compensate
for the loss of ApoE (Stone et al., 1998). Further high-
lighting a possible compensatory mechanism between
ApoE and clusterin is the study by DeMattos et al.
(2004) which showed only slight changes in plaque load
and deposition in PDAPP mice when either Clusterin or
Apoe was knockout but a much greater effect in the mice
where both were knocked out.
The increase in clusterin at the synapse which we
observed could be due to a number of factors including
neuronal stress. It is known that stress, and specifically
Ab induced stress, results in an increase in intracellular
clusterin and a decrease in extracellular clusterin (Killick
et al., 2014). A stress response could help explain the in-
crease in the amount of clusterin in Alzheimer’s disease.
Adding to this hypothesis is a study showing that clus-
terin is up-regulated in the cerebrospinal fluid (CSF) of
Alzheimer’s disease individuals and that higher CSF clus-
terin was associated with an increase in entorhinal cortex
atrophy (Desikan et al., 2014). Although this increase in
CSF could be a response to neuron degradation rather
than a causative factor it does lead to the question of
whether clusterin is involved in Ab-mediated synapse
loss. A question raised by our data is whether an increase
in clusterin has a protective or a detrimental effect on the
synapse. Clusterin can bind Ab, prevent fibrillization of
Ab, and prevent the loss of long-term potentiation and
memory when injected into a rat, which points towards a
protective role for clusterin in Alzheimer’s disease
(Cascella et al., 2013). On the other hand, knockout of
clusterin in rat primary neurons prevented Ab-induced
neuronal death which indicates the detrimental effects of
Ab may be at least in part due to clusterin (Killick et al.,
2014). However, it is worth noting the limitations of
these cell death data since supraphsyiological levels of Ab
are required to induce cell death in vitro. Furthermore
in vivo, pathological tau, not Ab, is thought to drive cell
death. In vitro studies have shown that incubation of Ab
fibrils and Ab oligomers with clusterin causes decreased
uptake of both fibrils and oligomers by microglia and
just oligomers by astrocytes (Mulder et al., 2014). This
could lead to the increased deposition of Ab as described
by DeMattos et al., but could also increase the amount
of Ab bound to apolipoproteins which could then target
that Ab to the synapse causing an increase in synapse
degeneration.
Clusterin is known to bind Ab in the extracellular
space and prevent fibrillization (Cascella et al., 2013).
This could indicate that the increase in Ab and clusterin
that we observe at the synapse is due to an internaliza-
tion of clusterin bound to Ab. However, other studies
have shown that intracellular clusterin is increased fol-
lowing Ab application indicating that up-regulation of
intracellular clusterin is a response to Ab accumulation in
the synapse (Killick et al., 2014). Of course, it is possible
that both occur in the cell and that cellular stress caused
by Ab at the synapse causes internalization of clusterin
bound to Ab causing a positive feedback loop. Recent
work in APP/PS1 mice crossed with clusterin knockout
mice demonstrates that the loss of clusterin shifts amyloid
deposition to cerebrovasculature due to a shift in clear-
ance to perivascular drainage pathways (Wojtas et al.,
2017). It is possible that our observed increased
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localization of clusterin in synapses in Alzheimer’s disease
may have implications beyond local synaptic protein
changes. Shifting subcellular clusterin localization could
potentially impact on the wider neuro-glial vascular unit,
but this requires further investigation.
It is possible that, similar to ApoE, clusterin has some
effects by acting via Ab but other effects via downstream
interactor molecules such as TREM2. These downstream
effects may influence the cellular milieu of the
Alzheimer’s disease brain and be of greater importance to
the overall neurodegeneration than the effects on Ab
alone. It is entirely likely that clusterin has multiple roles
in the brain and that these jobs depend in part upon sub-
cellular localization of the protein. To fully understand
the implications of this study, further investigation of the
role of this important risk factor on the synaptic changes
associated with Ab and Alzheimer’s disease is required.
The data presented here from human post-mortem brain
tissue highlight the importance of studying synaptic
effects of clusterin and its interactions with pathological
proteins in Alzheimer’s disease.
Supplementary material
Supplementary material is available at Brain
Communications online.
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